Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma Meeting Abstract
| Authors: | Omuro, A.; Beal, K.; Correa, D.; Chan, T.; DeAngelis, L.; Gavrilovic, I.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T.; Mellinghoff, I.; Grommes, C.; Panageas, K.; Reiner, A.; Barradas, R.; Abrey, L.; Gutin, P. |
| Abstract Title: | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma |
| Meeting Title: | 16th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in Conjunction with the AANS/CNS Section on Tumors |
| Journal Title: | Neuro-Oncology |
| Volume: | 13 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2011 Nov 17-20 |
| Meeting Location: | Orange County, CA |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2011-11-01 |
| Start Page: | iii59 |
| End Page: | iii60 |
| Language: | English |
| ACCESSION: | WOS:000297026600243 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/nor152 |
| PMCID: | PMC3199176 |
| Notes: | Meeting Abstract -- "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
